- Home
- Companies
- canada alberta
- tumor activity
Show results for
Refine by
Tumor Activity Suppliers Serving Alberta
28 companies found
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Immatics is developing Adoptive Cell Therapies, which are designed to leverage the power of T cells to actively infiltrate tumor tissue and kill tumor cells in a specific and serial ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed in ovarian cancer and ...
based inSolna, SWEDEN
Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® ...
Docetaxel micellar is a product candidate in early clinical development and is a novel formulation that combines XR-17 with docetaxel - a well-established cytotoxin, currently administered intravenously and containing ethanol. In June 2020, Vivesto ...
based inIllkirch-Graffenstaden, FRANCE
Transgene is a clinical-stage biotechnology company focused on designing and developing novel immunotherapeutics. Every day, we push the boundaries of innovation with our therapeutic vaccines and oncolytic viruses, to design better treatments for ...
TG4001 is an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 ...
based inOxford, UNITED KINGDOM
Blue Earth Diagnostics is an established molecular imaging company on a growth trajectory to provide innovative, well differentiated diagnostics solutions, informing patients and driving future therapies in cancer. Formed in 2014, Blue Earth ...
based inCambridge, MASSACHUSETTS (USA)
We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of ...
BOS-371 is a highly potent monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL1RAP), a prevalent tumor associated antigen driving tumor growth and immunosuppression. BOS-371 has also been Fc-engineered to enhance effector ...
based inPasadena, CALIFORNIA (USA)
Bench Chemicals, aka. BenchChem, is a leading supplier of high-quality chemicals and biochemicals for laboratory and R&D use. Our mission is to provide scientists and researchers worldwide with a one-stop source for innovative and basic chemicals ...
based inRedmond, WASHINGTON (USA)
SystImmune Inc. is a biopharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Our objective is to create biologics that ...
By combining bi-valency with bi-specificity in the tetravalent format, the dual checkpoint molecule utilizes avidity and bi-specificity to improve anti-cancer immune cell function. The specificity enhancement both synergistically enhance and expand ...
based inNangang Distric, TAIWAN
We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ...
TLC178 is our proprietary NanoX™ formulation of the anticancer drug vinorelbine, developed for the treatment of rhabdomyosarcoma (RMS), a rare form of soft tissue sarcoma that most frequently occurs in ...
based inSeattle, WASHINGTON (USA)
As the pioneer in the field of spatial biology, NanoString enables scientists across the globe to envision molecular interactions in three dimensions with three different systems, the nCounter Analysis System, the GeoMx Digital Spatial Profiler ...
The GeoMx Immune Pathways Panel is designed for targeted profiling of the tumor, tumor microenvironment, and tumor immune status. Profile up to 96 RNA targets with spatial resolution from a single tissue section using the GeoMx Digital Spatial ...
based inShanghai, CHINA
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...
ES014 is a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the adenosine and TGF-β pathways, two major immunosuppressive mechanisms in the tumor microenvironment (TME). Solid ...
based inNewark, DELAWARE (USA)
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across ...
Interleukin-21 (IL-21) is a secreted protein which belongs to the IL-15 / IL-21 family. Interleukin-21 / IL-21 belongs to a family of cytokines that bind to a composite receptor consisting of a private receptor (IL21R) and the common cytokine ...
based inMalmö, SWEDEN
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Oncoral is a novel oral irinotecan tablet in ...
Oncoral is a novel daily irinotecan chemotherapy in development. Irinotecan chemotherapy has an established potent anti-tumor effect – even in difficult to treat cancers. Oncoral is a daily irinotecan tablet with the potential to offer better ...
based inSouth San Francisco, CALIFORNIA (USA)
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Bio designs and optimizes gene circuits, which are created from novel and proprietary ...
The product profile of SENTI-301 has the potential to promote expansion and persistence of NK cells, and activate and recruit the body’s own immune cells into the solid tumor microenvironment for ...
based inWellesley Hills, MASSACHUSETTS (USA)
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 50 countries, TargetMol has evolved into one of ...
RMC-9805 is a novel, mutant-selective, covalent and oral KRASG12D (ON) inhibitor. A stable and high affinity triple complex is formed between RMC-9805, KRASG12D, and cyclophilin A, which inhibits signal transduction downstream of KRASG12D (ON) by ...
based inDowners Grove, ILLINOIS (USA)
Shared Imaging provides top-tier diagnostic imaging systems and services, optimizing MRI, PET/CT, CT, and Women's Health systems acquisition through innovative, cost-effective methods. Leveraging extensive expertise as owners, operators, and service ...
Shared Imaging provides PET/CT technology to hospitals, imaging centers, ambulatory/ED’s, and clinics. The company offers customizable solutions with technology options from various OEMs, allowing for tailored software packages, accessories ...
based inYongin-si, SOUTH KOREA
Txinno Bioscience is developing anti-cancer treatments focused on two intertwined aspects of physiology of tumor tissue. Tcino Bioscience Co., Ltd. has secured and built core platform technologies such as small molecule innovative anticancer drug ...
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), is a type II transmembrane protein with nucleotide pyrophosphatase and phosphodiesterase enzymatic activities. Recently, ENPP1 has been found to play an important role in ...
based inWroclaw, POLAND
Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based ...
Triple-negative breast cancer (TNBC) is a highly proliferative, rapidly growing, and aggressive form of cancer. TNBC can be further categorized into three types: Type 1 (also known as the “cold” type) is characterized by a tumor with low ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
Tumor immunotherapy utilizes active or passive methods to provoke tumor-specific immune responses in the body, harnessing their inhibitory and cytotoxic functions against tumor ...
based inFrankfurt, GERMANY
NeraCare develops and commercializes molecular diagnostic tests for patients with skin cancer. The tests provide actionable, tumor-specific information for each individual patient. The information is used to make improved treatment decisions, i.e. ...
Melanoma is a serious form of skin cancer that begins in cells known as melanocytes. While it is less common than basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), melanoma is far more dangerous because of its ability to spread to other ...